Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anaphylatoxins | 1 | 2021 | 34 | 0.22 | Why? |
| Acute-Phase Proteins | 1 | 2020 | 177 | 0.19 | Why? |
| Pancytopenia | 1 | 2020 | 113 | 0.19 | Why? |
| Psychomotor Performance | 1 | 2018 | 110 | 0.17 | Why? |
| Disposable Equipment | 1 | 2021 | 332 | 0.17 | Why? |
| Tryptophan | 1 | 2018 | 218 | 0.16 | Why? |
| Quality Assurance, Health Care | 1 | 2021 | 596 | 0.15 | Why? |
| Testosterone | 1 | 2021 | 596 | 0.15 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 526 | 0.14 | Why? |
| Ischemic Attack, Transient | 1 | 2018 | 439 | 0.14 | Why? |
| Aspartate Aminotransferases | 1 | 2020 | 1394 | 0.13 | Why? |
| Austria | 3 | 2021 | 1259 | 0.11 | Why? |
| Immunoglobulin G | 4 | 2021 | 21571 | 0.09 | Why? |
| Molecular Diagnostic Techniques | 2 | 2021 | 4239 | 0.09 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.08 | Why? |
| Quality Control | 2 | 2021 | 628 | 0.08 | Why? |
| Sirolimus | 1 | 2009 | 240 | 0.08 | Why? |
| Tacrolimus | 1 | 2009 | 435 | 0.08 | Why? |
| Neopterin | 1 | 2006 | 69 | 0.08 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.07 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2009 | 669 | 0.07 | Why? |
| Cyclosporine | 1 | 2009 | 449 | 0.07 | Why? |
| Liver Diseases | 1 | 2020 | 2698 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 13720 | 0.06 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.06 | Why? |
| Sensitivity and Specificity | 5 | 2021 | 22971 | 0.06 | Why? |
| Tandem Mass Spectrometry | 1 | 2009 | 1031 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2018 | 3361 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Cognition Disorders | 1 | 2006 | 574 | 0.05 | Why? |
| Mercaptopurine | 1 | 2020 | 68 | 0.05 | Why? |
| Enzyme-Linked Immunospot Assay | 1 | 2021 | 325 | 0.05 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2020 | 99 | 0.05 | Why? |
| Genome, Viral | 1 | 2021 | 13157 | 0.05 | Why? |
| CHO Cells | 1 | 2021 | 831 | 0.05 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.05 | Why? |
| Cricetulus | 1 | 2021 | 936 | 0.04 | Why? |
| Protein Subunits | 1 | 2021 | 755 | 0.04 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Kynurenine | 1 | 2018 | 140 | 0.04 | Why? |
| Methotrexate | 1 | 2020 | 471 | 0.04 | Why? |
| Alzheimer Disease | 1 | 2006 | 1020 | 0.04 | Why? |
| Light | 1 | 2018 | 306 | 0.04 | Why? |
| Random Allocation | 1 | 2018 | 773 | 0.04 | Why? |
| Stroke | 1 | 2018 | 8839 | 0.04 | Why? |
| Genes, Viral | 1 | 2021 | 1428 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.04 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.03 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2018 | 11497 | 0.03 | Why? |
| Flow Cytometry | 1 | 2021 | 2393 | 0.03 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.03 | Why? |
| Female | 10 | 2021 | 380317 | 0.03 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.03 | Why? |
| Melatonin | 1 | 2018 | 578 | 0.03 | Why? |
| Humans | 16 | 2021 | 930598 | 0.03 | Why? |
| Aged | 7 | 2021 | 215776 | 0.03 | Why? |
| Reagent Kits, Diagnostic | 1 | 2021 | 2149 | 0.03 | Why? |
| Middle Aged | 7 | 2021 | 270681 | 0.03 | Why? |
| Immunosuppressive Agents | 1 | 2009 | 6331 | 0.03 | Why? |
| Male | 9 | 2021 | 367725 | 0.03 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Resource Allocation | 1 | 2021 | 1771 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2021 | 2643 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| Adult | 6 | 2021 | 244371 | 0.02 | Why? |
| Binding Sites | 1 | 2021 | 6201 | 0.02 | Why? |
| Laboratories | 1 | 2021 | 2858 | 0.02 | Why? |
| HEK293 Cells | 1 | 2021 | 8394 | 0.02 | Why? |
| Mental Status Schedule | 1 | 2006 | 34 | 0.02 | Why? |
| Everolimus | 1 | 2009 | 215 | 0.02 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.02 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.02 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Cytomegalovirus | 1 | 2006 | 600 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2021 | 23402 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Animals | 1 | 2021 | 78931 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2006 | 7972 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2006 | 17020 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
| Registries | 1 | 2006 | 12327 | 0.00 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.00 | Why? |
Griesmacher's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(100)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(142)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_